Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds at the American Association for Cancer Research’s International Conference on Molecular Targets and Cancer Therapeutics

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year’s American Association for Cancer Research’s International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th.

CrownBio’s scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation.

On Saturday October 28th, Crown Bioscience’s Dr. Henry Li will deliver an oral presentation entitled, “Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments”, as part of the conference’s Challenges and Opportunities of Genomic Based Clinical Trials Plenary Session.

“I am excited to share Crown Bioscience’s cutting-edge research with colleagues at AACR- NCI-EORTC,” said Dr. Henry Li, Crown Bioscience’s Vice President of Translational Oncology. “The data presented will exhibit the utility of our clinically relevant PDX models to identify critical biomarkers and improve preclinical evaluation of cancer therapies.”

“Crown Bioscience is honored to play a leading role in presenting opportunities for scientific advancements at AACR-NCI-EORTC,” said Laurie Heilmann, Chief Business Officer. “The work of our dedicated scientific team exemplifies Crown Bioscience’s commitment to helping researchers solve global health challenges through continued innovation of our scientific translational platform.”

Delegates can request copies of the posters and learn more about Crown Bioscience’s scientific translational platform at booth 601. 

About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
marketing@CrownBioscience.com